A new study published in Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer
A new study published in Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer
Genprex's President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO CEO and Investor Conference and at the 2022 Diamond Equity Research Conference.
Academic Research Lab Uses ONCOPREX Delivery System to Restore FAS Expression in Mouse Metastatic Colon-Cancer Cells
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is a leader in gene therapy with a systemic gene therapy in development for non-small cell lung cancer (NSCLC).
original article: FDA Grants Fast Track Designation to Quaratusugene Ozeplasmid Immunogene Therapy Plus Pembrolizumab for NSCLC (cancernetwork.com)
original article: FDA Grants Fast Track Designation for Reqorsa in Combination with Keytruda for NSCLC (pharmacytimes.com)